Given that anti-CD38 therapy with daratumumab is effective in MM and that long-lived plasma cells exhibit elevated levels of CD38, there is a possibility that this treatment will lead to the therapeutically meaningful elimination of pathogenic long-lived plasma cells. The gene discussed is CD38; the disease is Miyoshi myopathy.